skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by /sup 19/F magnetic resonance spectroscopy in vivo

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

We have evaluated two fluorinated misonidazole analogues, Ro 07-0741 and CCI-103F, as potential probes for the non-invasive identification of hypoxic tumor cells by /sup 19/F magnetic resonance spectroscopy (MRS) in vivo. The equipment used was a 1.9 T Oxford Research Systems TMR-32 spectrometer, fitted with a 15 mm diameter surface coil. Signal was readily detectable, with similar intensity from EMT6 tumor, liver, and brain at early times (1-2 hr) after i.v. injection in BALB/c mice, indicative of an initial uniform biodistribution of parent probes. At later times (5-10 hr) there was a progressive reduction in signal intensity from brain and liver, but tumor levels remained constant or declined more slowly. This is illustrated by tumor/brain ratios at 6-7 hr of 2.9 (Ro 07-0741) and 4.2 (CCI-103F). In 4/5 mice analyzed at 20-24 hr after Ro 07-0741, and 1/2 following CCI-103F, tumor signal remained detectable. This occurred in the absence of parent probe as measured by HPLC, suggesting the involvement of a product of nitroreductive bioactivation. Studies with KHT and RIF-1 tumors in C3H/He mice showed a similar trend but retention in RIF-1 was less dramatic, and this was consistent with the known hypoxic fractions and comparative in vivo nitroreductase activities. These promising results support the continuing development of /sup 19/F nitroimidazole probes for non-invasive identification of hypoxic cells in vivo.

Research Organization:
St George's Hospital Medical School, London (England)
OSTI ID:
6252892
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Vol. 16:4
Country of Publication:
United States
Language:
English

Similar Records

Radiosensitization by a new potent nucleoside analog: 1-(1[prime],3[prime],4[prime]-trihydroxy-2[prime]-Butoxy)methyl-2-nitroimidazole(RP-343)
Journal Article · Tue Jun 15 00:00:00 EDT 1993 · International Journal of Radiation Oncology, Biology and Physics; (United States) · OSTI ID:6252892

A new potent radiosensitizer: 1-(2',3'-dideoxy-. cap alpha. -D-erythro-hex-2'-enopyranosyl)-2-nitroimidazole (RA-263)
Journal Article · Mon Mar 01 00:00:00 EST 1982 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:6252892

Evaluation and Immunohistochemical Qualification of Carbogen-Induced ΔR{sub 2}* as a Noninvasive Imaging Biomarker of Improved Tumor Oxygenation
Journal Article · Sun Sep 01 00:00:00 EDT 2013 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:6252892